Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 (ST6GALNAC6) is a sialyltransferase enzyme that catalyzes the transfer of sialic acid (N-acetylneuraminic acid, NeuAc) to glycolipids and glycoproteins, specifically forming alpha-2,6 linkages to N-acetylgalactosaminide (GalNAc) or N-acetylglucosaminide (GlcNAc) residues on cell surface molecules[3]. It is involved in the biosynthesis of branched disialyl structures and certain gangliosides, such as GD1alpha, from precursors like GM1b. ST6GALNAC6 preferentially acts on glycolipids, is implicated in the generation of antigens associated with cancer (such as disialyl Lewis a), and may regulate cell-cell and cell-matrix interactions by modifying surface sialylation patterns[3]. Potentially, changes in ST6GALNAC6 activity can affect the composition of gangliosides in cells, with functional consequences for tumor progression and metastasis[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 (ST6GALNAC6).